Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Con...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae288 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:60d4ac21e05c467fbf3ab94fb38ae288 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:60d4ac21e05c467fbf3ab94fb38ae2882021-12-02T08:38:14ZBrolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration1177-5483https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae2882019-07-01T00:00:00Zhttps://www.dovepress.com/brolucizumab-evidence-to-date-in-the-treatment-of-neovascular-age-rela-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Consultants of New York, New York, NY, USA; 4Department of Ophthalmology, New York University School of Medicine, New York, NY, USAAbstract: Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation.Keywords: neovascular age-related macular degeneration, brolucizumab, vascular endothelial growth factor Yannuzzi NAFreund KBDove Medical PressarticleNeovascular Age-Related Macular DegenerationBrolucizumabVascular Endothelial Growth FactorOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1323-1329 (2019) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Neovascular Age-Related Macular Degeneration Brolucizumab Vascular Endothelial Growth Factor Ophthalmology RE1-994 |
spellingShingle |
Neovascular Age-Related Macular Degeneration Brolucizumab Vascular Endothelial Growth Factor Ophthalmology RE1-994 Yannuzzi NA Freund KB Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
description |
Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Consultants of New York, New York, NY, USA; 4Department of Ophthalmology, New York University School of Medicine, New York, NY, USAAbstract: Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation.Keywords: neovascular age-related macular degeneration, brolucizumab, vascular endothelial growth factor
|
format |
article |
author |
Yannuzzi NA Freund KB |
author_facet |
Yannuzzi NA Freund KB |
author_sort |
Yannuzzi NA |
title |
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_short |
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_full |
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_fullStr |
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_full_unstemmed |
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
title_sort |
brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration |
publisher |
Dove Medical Press |
publishDate |
2019 |
url |
https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae288 |
work_keys_str_mv |
AT yannuzzina brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration AT freundkb brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration |
_version_ |
1718398419695828992 |